Journal of Neurology

, Volume 259, Issue 11, pp 2293–2298

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

  • Olivier Outteryck
  • Jean-Claude Ongagna
  • Alain Duhamel
  • Hélène Zéphir
  • Nicolas Collongues
  • Arnaud Lacour
  • Marie-Céline Fleury
  • Anne-Sophie Berteloot
  • Frédéric Blanc
  • Marianne Giroux
  • Patrick Vermersch
  • Jérôme de Sèze
Original Communication

DOI: 10.1007/s00415-012-6487-5

Cite this article as:
Outteryck, O., Ongagna, JC., Duhamel, A. et al. J Neurol (2012) 259: 2293. doi:10.1007/s00415-012-6487-5

Abstract

To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.

Keywords

Multiple sclerosis Natalizumab JCV Progressive multiple leukoencephalopathy 

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Olivier Outteryck
    • 1
  • Jean-Claude Ongagna
    • 2
  • Alain Duhamel
    • 3
  • Hélène Zéphir
    • 1
  • Nicolas Collongues
    • 2
  • Arnaud Lacour
    • 1
  • Marie-Céline Fleury
    • 2
  • Anne-Sophie Berteloot
    • 1
  • Frédéric Blanc
    • 2
  • Marianne Giroux
    • 1
  • Patrick Vermersch
    • 1
  • Jérôme de Sèze
    • 2
  1. 1.Department of NeurologyUniversity Hospital of Lille, Université Lille Nord de France, Hôpital Roger SalengroLille CedexFrance
  2. 2.Department of NeurologyUniversity Hospital of Strasbourg, Hôpital CivilStrasbourgFrance
  3. 3.Department of BiostatisticsCERIM EA2694Lille CedexFrance

Personalised recommendations